Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye.

Raghuram, A; Saravanan, V R; Narendran, V

Raghuram, A; Saravanan, V R; Narendran, V.

Indian J Ophthalmol ; 2007 Nov-Dec; 55(6): 460-2

Article in English | IMSEAR | ID: sea-72221

ABSTRACT

ABSTRACT

Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six months of follow-up.

Subject(s)

Adult; Angiogenesis Inhibitors/administration & dosage; Anterior Chamber/blood supply; Antibodies, Monoclonal/administration & dosage; Blindness/complications; Female; Follow-Up Studies; Humans; Injections; Neovascularization, Pathologic/complications; Pain/complications; Time Factors; Vascular Endothelial Growth Factor A/antagonists & inhibitors

Fulltext

XML

Search on Google

Full text: Available Index: IMSEAR (South-East Asia) Main subject: Pain / Time Factors / Female / Humans / Blindness / Follow-Up Studies / Adult / Angiogenesis Inhibitors / Vascular Endothelial Growth Factor A / Injections Type of study: Observational study / Prognostic study Language: English Journal: Indian J Ophthalmol Year: 2007 Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google